Literature DB >> 19893210

suPAR: the molecular crystal ball.

Maria Thunø1, Betina Macho, Jesper Eugen-Olsen.   

Abstract

soluble urokinase Plasminogen Activator Receptor (suPAR) levels reflect inflammation and elevated suPAR levels are found in several infectious diseases and cancer. suPAR exists in three forms; suPAR(I-III), suPAR(II-III) and suPAR(I) which show different properties due to structural differences. Studies suggest that full-length suPAR is a regulator of uPAR/uPA by actingas uPA-scavenger, whereas the cleaved suPAR(II-III) act as a chemotactic agent promoting the immune response via the SRSRY sequence in the linker-region. This review focus on the various suPAR fragments and their involvement in inflammation and pathogenic processes. We focus on the molecular mechanisms of the suPAR fragments and the link to the inflammatory process,as this could lead to medical applications in infectious and pathological conditions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19893210      PMCID: PMC3835059          DOI: 10.3233/DMA-2009-0657

Source DB:  PubMed          Journal:  Dis Markers        ISSN: 0278-0240            Impact factor:   3.434


  190 in total

1.  Is there clinical value in measuring suPAR levels in FSGS?

Authors:  Sanja Sever; Howard Trachtman; Changli Wei; Jochen Reiser
Journal:  Clin J Am Soc Nephrol       Date:  2013-07-25       Impact factor: 8.237

Review 2.  Primary focal and segmental glomerulosclerosis and soluble factor urokinase-type plasminogen activator receptor.

Authors:  Hernán Trimarchi
Journal:  World J Nephrol       Date:  2013-11-06

3.  Soluble Urokinase Plasminogen Activator Receptor and Decline in Kidney Function in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Salim S Hayek; Douglas P Landsittel; Changli Wei; Martin Zeier; Alan S L Yu; Vicente E Torres; Sharin Roth; Christina S Pao; Jochen Reiser
Journal:  J Am Soc Nephrol       Date:  2019-06-06       Impact factor: 10.121

Review 4.  Are there new approaches for diagnosis, therapy guidance and outcome prediction of sepsis?

Authors:  Dubravka Kojic; Benedikt H Siegler; Florian Uhle; Christoph Lichtenstern; Peter P Nawroth; Markus A Weigand; Stefan Hofer; Thorsten Brenner
Journal:  World J Exp Med       Date:  2015-05-20

5.  Plasma suPAR as a prognostic biological marker for ICU mortality in ARDS patients.

Authors:  Diederik G P J Geboers; Friso M de Beer; Anita M Tuip-de Boer; Tom van der Poll; Janneke Horn; Olaf L Cremer; Marc J M Bonten; David S Y Ong; Marcus J Schultz; Lieuwe D J Bos
Journal:  Intensive Care Med       Date:  2015-06-23       Impact factor: 17.440

6.  Beneficial Effects of Cannabis on Blood-Brain Barrier Function in Human Immunodeficiency Virus.

Authors:  Ronald J Ellis; Scott Peterson; Mariana Cherner; Erin Morgan; Rachel Schrier; Bin Tang; Martin Hoenigl; Scott Letendre; Jenny Iudicello
Journal:  Clin Infect Dis       Date:  2021-07-01       Impact factor: 9.079

Review 7.  Extrarenal determinants of kidney filter function.

Authors:  Eunsil Hahm; Vasil Peev; Jochen Reiser
Journal:  Cell Tissue Res       Date:  2017-05-30       Impact factor: 5.249

8.  Soluble Urokinase-type Plasminogen Activator Receptor Predicts All-cause 5-Year Mortality in Ischemic Stroke and TIA.

Authors:  Juha Onatsu; Mikko Taina; Pirjo Mustonen; Marja Hedman; Antti Muuronen; Otso Arponen; Miika Korhonen; Pekka Jäkälä; Ritva Vanninen; Kari Pulkki
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

9.  The pro-inflammatory biomarker soluble urokinase plasminogen activator receptor (suPAR) is associated with incident type 2 diabetes among overweight but not obese individuals with impaired glucose regulation: effect modification by smoking and body weight status.

Authors:  A Heraclides; T M Jensen; S S Rasmussen; J Eugen-Olsen; S B Haugaard; K Borch-Johnsen; A Sandbæk; T Lauritzen; D R Witte
Journal:  Diabetologia       Date:  2013-04-24       Impact factor: 10.122

10.  Usefulness of suPAR in the risk stratification of patients with sepsis admitted to the emergency department.

Authors:  Ivo Casagranda; Chiara Vendramin; Tiziana Callegari; Matteo Vidali; Alessandra Calabresi; Giovanna Ferrandu; Gianfranco Cervellin; Mario Cavazza; Giuseppe Lippi; Isabella Zanotti; Sophie Negro; Andrea Rocchetti; Carlo Arfini
Journal:  Intern Emerg Med       Date:  2015-07-09       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.